The three paradoxes of progress in medicine

framework · David Wootton

"I shall be arguing for a paradoxical thesis: that progress in medicine has been ineffectual, immoral and postponed. Each of these claims will surprise some readers, but each is, I believe, well founded."
Wootton, Bad Medicine (Oxford University Press, 2006), p. 26 (Introduction).

SUMMARY

Wootton's three paradoxes are the master organizing claims of *Bad Medicine* and the most concise statement of its central provocation. (1) Ineffectual: medicine's contribution to the population-level increase in life expectancy from 1800 to 2000 was small relative to sanitation, nutrition, and behavioural change. (2) Immoral: many of the most effective modern interventions were available decades before they were adopted (Lind's scurvy trial 1747 to 1795 adoption; Snow's cholera identification 1854 to general acceptance c. 1875; Doll and Bradford Hill's smoking trial 1950 to public-health adoption in the 1970s and 1980s), and the delay in each case cost preventable lives. (3) Postponed: the genuine therapeutic capacity of medicine begins between 1865 (Lister's first antiseptic operation) and 1941 (the first clinical application of penicillin), over 2,000 years after Hippocrates. The three paradoxes are the archive's framing for the proposition that elite-longevity medicine is a contemporary instance of a recurring pattern (effectual claims unsupported by evidence, immoral delays in adopting cheap interventions, postponed translation of basic science into actual therapeutic gain) rather than a novel domain governed by novel rules.

APPLIES TO CASES

SOURCES

Bad Medicine: Doctors Doing Harm Since Hippocrates

NOTES

The three paradoxes are the archive’s framing claim. The longevity-industry narrative is that medical innovation has been the primary driver of life extension and that further life extension will come from further medical innovation. The three-paradoxes claim is that this narrative is approximately the opposite of the historical record: medical innovation has been a minor contributor to life extension; the genuinely effective innovations have repeatedly been delayed by decades or centuries by institutional and cultural factors; and the periods of greatest investment in medical research have not been the periods of greatest population-level gain. The implication for elite-longevity medicine is structural rather than rhetorical: the proposition that a high-cost, high-credentialing, biomarker-driven intervention class is going to produce a major population-level life-extension gain has, on the historical record, no precedent and considerable counter-evidence. The three paradoxes are the archive’s reason for skepticism about the contemporary domain, not a generic argument for therapeutic nihilism.